Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temsirolimus and Pemetrexed in Recurrent/Refractory NSCLC
NCT00921310Phase 2Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Sep 2009
- Primary completion
- Jan 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of temsirolimus in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Washington University School of Medicine. Primary endpoints: Maximum Tolerated Dose of Pemetrexed, Maximum Tolerated Dose of Temsirolimus and 4 more. Started Sep 2009; status: terminated.
02
Drugs
temsirolimus
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00921310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00921310.